- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00724867
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
March 10, 2016 updated by: Human Genome Sciences Inc., a GSK Company
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a long-term continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States.
This study is to evaluate the long-term safety and efficacy of belimumab (LymphoStat-B™) in subjects with SLE disease.
Study Type
Interventional
Enrollment (Actual)
268
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- GSK Investigational Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- GSK Investigational Site
-
Tucson, Arizona, United States, 85724
- GSK Investigational Site
-
-
California
-
Long Beach, California, United States, 90806
- GSK Investigational Site
-
Los Angeles, California, United States, 90048
- GSK Investigational Site
-
Los Angeles, California, United States, 90033
- GSK Investigational Site
-
Upland, California, United States, 91786
- GSK Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- GSK Investigational Site
-
-
Florida
-
Aventura, Florida, United States, 33180
- GSK Investigational Site
-
Orlando, Florida, United States, 32806
- GSK Investigational Site
-
Tampa, Florida, United States, 33614
- GSK Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- GSK Investigational Site
-
Chicago, Illinois, United States, 60612
- GSK Investigational Site
-
-
Indiana
-
Munster, Indiana, United States, 46321
- GSK Investigational Site
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- GSK Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- GSK Investigational Site
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- GSK Investigational Site
-
Cumberland, Maryland, United States, 21502
- GSK Investigational Site
-
Hagerstown, Maryland, United States, 21740
- GSK Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-5542
- GSK Investigational Site
-
Lansing, Michigan, United States, 48910
- GSK Investigational Site
-
-
New York
-
Bronx, New York, United States, 10461
- GSK Investigational Site
-
Brooklyn, New York, United States, 11203
- GSK Investigational Site
-
Great Neck, New York, United States, 11021
- GSK Investigational Site
-
Manhasset, New York, United States, 11030
- GSK Investigational Site
-
New York, New York, United States, 10016
- GSK Investigational Site
-
Rochester, New York, United States, 14618
- GSK Investigational Site
-
Smithtown, New York, United States, 11787
- GSK Investigational Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- GSK Investigational Site
-
Greenville, North Carolina, United States, 27834
- GSK Investigational Site
-
Winston-Salem, North Carolina, United States, 27157
- GSK Investigational Site
-
-
Ohio
-
Columbus, Ohio, United States, 43203
- GSK Investigational Site
-
Dayton, Ohio, United States, 45417
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 74104
- GSK Investigational Site
-
Tulsa, Oklahoma, United States, 74104
- GSK Investigational Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, United States, 15217
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- GSK Investigational Site
-
Charleston, South Carolina, United States, 29406
- GSK Investigational Site
-
Greenville, South Carolina, United States, 29601
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78705
- GSK Investigational Site
-
Houston, Texas, United States, 77074
- GSK Investigational Site
-
Houston, Texas, United States, 77004
- GSK Investigational Site
-
Houston, Texas, United States, 77034
- GSK Investigational Site
-
San Antonio, Texas, United States, 78232
- GSK Investigational Site
-
Sugar Land, Texas, United States, 77479
- GSK Investigational Site
-
-
Virginia
-
Arlington, Virginia, United States, 22205-3606
- GSK Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98133
- GSK Investigational Site
-
-
Wisconsin
-
Onalaska, Wisconsin, United States, 54650
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have completed the HGS1006-C1056 protocol in the United States through Week 72 visit.
- Be able to receive 1st dose of belimumab for HGS 1006-c1066 four weeks after last dose in HGS1006-c1056.
Exclusion Criteria:
- Have developed any other medical disease or condition that has made the subject unsuitable for this study in the opinion of their physician.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Belimumab 1 mg/kg
Belimumab 1 mg/kg IV every 28 days
|
Belimumab 1 mg/kg IV over one hour every 28 days
Other Names:
|
EXPERIMENTAL: Belimumab 10 mg/kg
Belimumab 10 mg/kg IV every 28 days
|
Belimumab 10 mg/kg IV over one hour every 28 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)
Time Frame: Up to Week 440
|
An AE is defined as any untoward medical occurrence in a participant (par.)
temporally associated with the use of a investigational product (IP), whether or not considered related to the IP.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an IP.
An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function.
Only those participants available at the specified time points (represented by n=X, in the category titles) were analyzed.
|
Up to Week 440
|
AE Rates by System Organ Class (SOC) During the Study
Time Frame: Up Week 440
|
AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits.
Only treatment-emergent adverse events (AEs) are summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate = 100* Number of Events / Participant Years.
Participant years were calculated as sum across all participants ([last visit of interval day - first visit of interval day + 1]/365).
Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.
|
Up Week 440
|
SAE Rates by System Organ Class (SOC) During the Study
Time Frame: Up to Week 440
|
SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits.
Only treatment-emergent SAEs are summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate = 100* Number of Events / participants Years.
participants years were calculated as = sum across all participants ([last visit of interval day - first visit of interval day + 1]/365).
participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.
|
Up to Week 440
|
Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points
Time Frame: Up to Week 440
|
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Change from Baseline in APTT and PT is summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Neutrophils Segmented and Platelets at the Indicated Time Points
Time Frame: Up to Week 440
|
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to440 weeks and at follow-up (up to 8 weeks post last infusion).
Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, neutrophils segmented and platelets is summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Change From Baseline in Erythrocytes at the Indicated Time Points
Time Frame: Up to Week 440
|
Hematology parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Change from Baseline in erythrocytes is summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Change From Baseline in Hematocrit at the Indicated Time Points
Time Frame: Up to Week 440
|
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Change from Baseline in hematocrit is summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Change From Baseline in Hemoglobin at the Indicated Time Points
Time Frame: Up to Week 440
|
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Change from Baseline in hemoglobin is summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Change From Baseline in Albumin and Protein at the Indicated Time Points
Time Frame: Up to Week 440
|
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Change from Baseline in albumin and protein is summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Change From Baseline in Blood Urea Nitrogen, Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points
Time Frame: Up to Week 440
|
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Change from Baseline in blood urea nitrogen, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points
Time Frame: Up to Week 440
|
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Change from Baseline in urate, creatinine and bilirubin is summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Change From Baseline in Creatinine Clearance at the Indicated Time Points
Time Frame: Up to Week 440
|
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Change from Baseline in creatinine clearance is summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Change From Baseline in BUN/Creatinine at the Indicated Time Points
Time Frame: Up to Week 440
|
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Change from Baseline in BUN/creatinine is summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points
Time Frame: Up to Week 432
|
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit.
Change from Baseline in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase and lactate dehydrogenase is summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 432
|
Number of Participants With the Indicated Immunogenic Response
Time Frame: Up to Week 440
|
Immunogenic response was assessed by binding confirmatory assay at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Number of participants with the indicated immunogenic response are summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Results of binding confirmatory assay were categorized as negative, persistent positive (defined as a positive immunogenic response that occurs at least 2 consecutive assessments or a single result at the final assessment) or transient positive (defined as a single positive immunogenic response that does not occur at the final assessment).
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Systolic Blood Pressure and Diastolic Blood Pressure at Indicated Time Points.
Time Frame: Up to Week 432
|
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 432
|
Percentage of Participants With at Least 25% Increase From Baseline in Creatinine at Indicated Time Points.
Time Frame: Up to Week 440
|
Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Percentage of participants with at least 25% increase from baseline in creatinine are summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Percentage of Participants With at Least 25% Reduction From Baseline in Creatinine at Indicated Time Points. Amongst Subjects With Abnormal (>124 Umol/L) Creatinine at Baseline by Year Interval.
Time Frame: Up to Week 440
|
Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion).
Percentage of participants with at least 25% reduction from baseline in creatinine are summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Serum Immunoglobulins Below the Lower Limit of Normal at Indicated Time Points.
Time Frame: Up to Week 392
|
Serum immunoglobulin G (IgG) was collected at Baseline (BL) (Day 0), at Week 24 and Week 48 in first year, at Week 48 in subsequent years up to 8 years and at follow-up (up to 8 weeks post last infusion).
Number of participants with serum immunoglobulins below the lower limit of normal (LLN) (<0.5 nanograms per milliliter [ng/mL]) are summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 392
|
Percentage of Participants Achieving SRI Response at Indicated Time Points
Time Frame: Up to Week 440
|
The percentage of participants achieving a SLE Responder Index (SRI) response at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion) are summarized.
The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Response is defined as:>=4 point reduction from the BL in the safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of <0.30 points from the BL) in Physicians Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the BL.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Observed Anti-double Stranded DNA Levels at Indicated Time Points.
Time Frame: Up to Week 432
|
Anti-double stranded deoxyribonucleic acid (anti-dsDNA) levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks in participants who were positive at baseline (anti-dsDNA >=30 International Units/milliliter [IU/mL]).
Observed anti-dsDNA levels are summarized.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 432
|
Median Percent Change From Baseline in Anti-double Stranded DNA at Indicated Time Points.
Time Frame: Up to Week 432
|
Anti-dsDNA levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants who were positive at baseline (anti-dsDNA ≥30 IU/mL).
Median percent change from Baseline in anti-dsDNA levels are summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline).
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 432
|
Observed Complement C3 and C4 Levels at Indicated Time Points
Time Frame: Up to Week 440
|
Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at exit visit in participants with low complements at Baseline (C3 <90 milligram per deciliter (mg/dL) and C4 <16 mg/dL).
Observed complement C3 and C4 levels are summarized.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 440
|
Median Percent Change From Baseline in Complement C3 and C4 Levels at Indicated Time Points
Time Frame: Up to Week 432
|
Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants with low complements at Baseline (C3 <90 milligrams per decilitre (mg/dL) and C4 <16 mg/dL).
Median percent change from Baseline in complement C3 and C4 levels are summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline).
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 432
|
Percent of Participants With Daily Prednisone Dose Reduction at Indicated Time Points.
Time Frame: Up to Week 432
|
Trends for reduction in prednisone use in participants receiving belimumab were observed up to 432 weeks.
Percentage of participants with daily prednisone dose reduced to <=7.5 mg/day from >7.5 mg/kg at the Baseline are summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 432
|
Percent of Participants With >= 50% Reduction in Proteinuria at Indicated Time Points.
Time Frame: Up to Week 432
|
Proteinuria is defined as the presence of an excess of serum proteins in the urine.
Trends for reduction in proteinuria in participants receiving belimumab were assessed up to 432 weeks and at Exit visit.
Percentage of participants with >= 50% reduction in proteinuria among participants with Baseline proteinuria >0.5 g/24 hour (hr) are summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 432
|
Observed B-cell Levels at Indicated Time Points.
Time Frame: Up to Week 432
|
B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit.
Observed absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized.
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 432
|
Median Percent Change From Baseline in B Cell Levels at Indicated Time Points.
Time Frame: Up to Week 432
|
B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit.
Median percent change from Baseline in absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized.
The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline).
Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
|
Up to Week 432
|
Percentage of Participants With Worsening in SLICC/ACR Damage Index at Indicated Time Points
Time Frame: Up to Week 384
|
Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) Damage Index is a tool used to assess non-reversible organ damage in SLE patients.
Damage Index is used to assess 12 systems by 41 items.
Score is given as 1 or sometimes 2, if occur more than once, so that that the maximum possible score is 47.
Higher damage index scores early in disease are associated with a poor prognosis and with increased mortality.
Damage index was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years.
Percentage of participants with worsening in damage index (change >0) are summarized.
The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Only those participants available at the specified time points were analyzed ( n=X).
|
Up to Week 384
|
Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Time Point
Time Frame: Up to Week 384
|
The SF-36v2 is a participant-reported short form survey to measure functional health and well-being.
There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health.
SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants.
The lower the score the more disability and the higher the score the less disability.
The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from BL was calculated as the individual post-BL value minus the BL value.
Only those participants available at the specified time points were analyzed ( n=X).
|
Up to Week 384
|
Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Timepoints
Time Frame: Up to Week 384
|
The SF-36v2 is a participant-reported survey to measure functional health and well-being.
There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health.
SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants.
The lower the score the more disability and the higher the score the less disability.
The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from BL was calculated as the individual post-BL value minus the BL value.
Only those participants available at the specified time points were analyzed ( n=X).
|
Up to Week 384
|
Change From Baseline in FACIT-Fatigue Scale Total Score at Indicated Time Point
Time Frame: Up to Week 384
|
The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days.
FACIT-Fatigue scale total score was assessed at BL (Day 0), Wk 48 in first year, at Wk 48 in subsequent Yrs up to 8 Yrs.The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52).
Change from BL in FACIT-Fatigue scale total score are summarized.
The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Change from BL was calculated as the individual post-BL value minus the BL value.
A negative change from BL represents a worsening condition.
Only those participants available at the specified time points were analyzed ( n=X).
|
Up to Week 384
|
Percentage of Participants With Improvement in FACIT-Fatigue Scale Score Exceeding the MCID at Indicated Time Points
Time Frame: Up to Week 384
|
The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days.
FACIT-Fatigue scale total score was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years.
The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52).
Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the minimum clinically important difference (MCID) (>=4 points) are summarized.
Only those participants available at the specified time points were analyzed ( n=X).
|
Up to Week 384
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. Arthritis Rheumatol. 2018 Jun;70(6):868-877. doi: 10.1002/art.40439. Epub 2018 Apr 25.
- Strand V, Berry P, Lin X, Asukai Y, Punwaney R, Ramachandran S. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment. Arthritis Care Res (Hoboken). 2019 Jun;71(6):829-838. doi: 10.1002/acr.23788. Epub 2019 Apr 29.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (ACTUAL)
March 1, 2015
Study Completion (ACTUAL)
March 1, 2015
Study Registration Dates
First Submitted
July 28, 2008
First Submitted That Met QC Criteria
July 29, 2008
First Posted (ESTIMATE)
July 30, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
March 28, 2016
Last Update Submitted That Met QC Criteria
March 10, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 112233
- HGS1006-C1066 (OTHER: Human Genome Sciences)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...CompletedSystemic Lupus Erythematosus | Cutaneous Lupus ErythematosusSpain, Bulgaria, Germany, Moldova, Republic of, North Macedonia, Ukraine
Clinical Trials on Belimumab 1 mg/kg
-
Human Genome Sciences Inc.CompletedArthritis, RheumatoidUnited States
-
Human Genome Sciences Inc., a GSK CompanyGlaxoSmithKlineCompletedLupus Erythematosus, Discoid
-
Human Genome Sciences Inc.CompletedLupus Erythematosus, SystemicUnited States, Canada
-
Human Genome Sciences Inc.GlaxoSmithKlineCompletedSystemic Lupus ErythematosusUnited States, Spain, Israel, Netherlands, Canada, Germany, Poland, Romania, Puerto Rico, Costa Rica, Belgium, Slovakia, United Kingdom, Mexico, Italy, Austria, Czech Republic, Sweden, France
-
Human Genome Sciences Inc.GlaxoSmithKlineCompletedSystemic Lupus ErythematosusHong Kong, Taiwan, Korea, Republic of, India, Chile, Argentina, Philippines, Colombia, Brazil, Romania, Australia, Peru, Russian Federation
-
GlaxoSmithKlineHuman Genome Sciences Inc.Completed
-
Human Genome Sciences Inc.GlaxoSmithKlineCompleted
-
MedImmune LLCCompletedHealthy SubjectsUnited States
-
Bio Sidus SACompleted
-
Healthgen Biotechnology Corp.RecruitingEmphysema Secondary to Congenital AATDUnited States